The VIVA-MIND Study is a Phase 2 national multi-site clinical trial testing an investigational drug called Varoglutamstat (PQ912) for people with a diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or mild probable Alzheimer’s disease. The trial is designed to determine if the study drug may delay or slow the progression of the symptoms of early Alzheimer’s disease.
You may be able to join this study if you:
- Are 50 to 89 years old
- Are diagnosed with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or mild probable Alzheimer’s disease
- Are taking at least one Alzheimer’s medication for the treatment of Alzheimer’s symptoms
- Have a study partner who can go to some study visits to answer questions about the study participant’s symptoms